Mucocutaneous lymph node syndrome
Drug research and approvals for mucocutaneous lymph node syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 11 studies of mucocutaneous lymph node syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 11
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Statins Study in Children of Acute Kawasaki Disease With Coronary Artery AbnormalitiesNCT07530640 · Phase 3 · Children's Hospital of Fudan University · starts Jun 8, 2026
- Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for…NCT07405658 · Not reported · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · starts Feb 1, 2026
- Kawasaki MATCH TrialNCT07291245 · Not applicable · University of California, San Diego · starts Mar 1, 2025
- Cardiovascular Risk in Children With Chronic Conditions StudyNCT07086989 · Not reported · Semmelweis University · starts Apr 1, 2025
- Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 YearsNCT06993636 · Not reported · Children's Hospital of Fudan University · starts Jan 1, 2023
- Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki DiseaseNCT06978439 · Phase 4 · Children's Hospital of Fudan University · starts Jan 10, 2024
- European and North Indian Cohort of KaWasaki dIseaseNCT06305611 · Not reported · Meyer Children's Hospital IRCCS · starts Jul 13, 2021
- Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki DiseaseNCT05643651 · Phase 4 · Children's Hospital of Fudan University · starts Jun 1, 2025
- A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients…NCT04656184 · Phase 3 · Assistance Publique - Hôpitaux de Paris · starts Oct 20, 2023
Approved 1
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
Phase 3 4
- InfliximabTNF-alpha inhibitor
- AnakinraInterleukin-1 receptor antagonist
- AspirinCyclooxygenase inhibitor
- Polyethylene glycolOsmotic laxative
Phase 2 4
- EtanerceptTNF-alpha inhibitor
- PravastatinHMG-CoA reductase inhibitor
- CanakinumabInterleukin-1 beta inhibitor
- DefibrotideAdenosine A2 receptor agonist
Phase 1 or earlier 1
- AtorvastatinHMG-CoA reductase inhibitor
How its trials ended
56 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 9 whose ending is known, 56% met their primary endpoint, 11% missed it and 33% stopped early.
- Completed, result not reported1934%
- Status unknown1527%
- Ongoing1323%
- Met its primary endpoint59%
- Stopped: other or unclear35%
- Missed its primary endpoint12%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 23, 2007 | Flebogamma DIF (previously Flebogammadif)Human normal immunoglobulin | Instituto Grifols S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA